Medivation Branches Out With Phase III PARP Inhibitor From BioMarin
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal is structured with significant upfront cash at $410m, but relatively low earn-out potential for a Phase III cancer candidate. It also gives Medivation two late-stage oncology compounds beyond Xtandi; CEO David Hung outlines strategy.